Suppr超能文献

由抗重组V抗原和蛋白A-V抗原融合肽介导的对耶尔森菌的被动免疫。

Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

作者信息

Motin V L, Nakajima R, Smirnov G B, Brubaker R R

机构信息

Department of Microbiology, Michigan State University, East Lansing 48824-1101.

出版信息

Infect Immun. 1994 Oct;62(10):4192-201. doi: 10.1128/iai.62.10.4192-4201.1994.

Abstract

LcrV (V antigen), a known unstable 37.3-kDa monomeric peptide encoded on the ca. 70-kb Lcr plasmid of Yersinia pestis, Yersinia pseudotuberculosis, and Yersinia enterocolitica, has been implicated as a regulator of the low-calcium response, virulence factor, and protective antigen. In this study, lcrV of Y. pestis was cloned into protease-deficient Escherichia coli BL21. The resulting recombinant V antigen underwent marked degradation from the C-terminal end during purification, yielding major peptides of 36, 35, 34, and 32 to 29 kDa. Rabbit gamma globulin raised against this mixture of cleavage products provided significant protection against 10 minimum lethal doses of Y. pestis (P < 0.01) and Y. pseudotuberculosis (P < 0.02). To both stabilize V antigen and facilitate its purification, plasmid pPAV13 was constructed so as to encode a fusion of lcrV and the structural gene for protein A (i.e., all but the first 67 N-terminal amino acids of V antigen plus the signal sequence and immunoglobulin G-binding domains but not the cell wall-associated region of protein A). The resulting fusion peptide, termed PAV, could be purified to homogeneity in one step by immunoglobulin G affinity chromatography and was stable thereafter. Rabbit polyclonal gamma globulin directed against PAV provided excellent passive immunity against 10 minimum lethal doses of Y. pestis (P < 0.005) and Y. pseudotuberculosis (P < 0.005) but was ineffective against Y. enterocolitica. Protection failed after absorption with excess PAV, cloned whole V antigen, or a large (31.5-kDa) truncated derivative of the latter but was retained (P < 0.005) upon similar absorption with a smaller (19.3-kDa) truncated variant, indicating that at least one protective epitope resides internally between amino acids 168 and 275.

摘要

LcrV(V抗原)是一种已知的不稳定的37.3 kDa单体肽,由鼠疫耶尔森菌、假结核耶尔森菌和小肠结肠炎耶尔森菌约70 kb的Lcr质粒编码,被认为是低钙反应的调节剂、毒力因子和保护性抗原。在本研究中,将鼠疫耶尔森菌的lcrV克隆到蛋白酶缺陷型大肠杆菌BL21中。所得重组V抗原在纯化过程中从C末端发生明显降解,产生36、35、34以及32至29 kDa的主要肽段。针对这种裂解产物混合物产生的兔γ球蛋白对10个最小致死剂量的鼠疫耶尔森菌(P < 0.01)和假结核耶尔森菌(P < 0.02)提供了显著保护。为了稳定V抗原并便于其纯化,构建了质粒pPAV13,以编码lcrV与蛋白A结构基因的融合体(即V抗原除前67个N末端氨基酸外加上信号序列和免疫球蛋白G结合结构域,但不包括蛋白A的细胞壁相关区域)。所得融合肽称为PAV,可通过免疫球蛋白G亲和色谱一步纯化至同质,且此后稳定。针对PAV的兔多克隆γ球蛋白对10个最小致死剂量的鼠疫耶尔森菌(P < 0.005)和假结核耶尔森菌(P < 0.0

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13db/303095/c8f3c6864d37/iai00010-0109-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验